Skip to main content

Advertisement

SpringerLink
Log in

Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder

  • Original Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

Introduction and hypothesis

We evaluated changes in urinary nerve growth factor (NGF) and NGF/creatinine (NGF/Cr) levels after increasing the dosage of solifenacin in overactive bladder patients.

Methods

The study groups included 59 overactive bladder (OAB) patients and 20 healthy subjects as controls. We measured NGF at baseline for the patients and controls, and used the Overactive Bladder Awareness Tool (OAB-V8) to evaluate urinary symptoms. All patients received a treatment of solifenacin 5 mg for 6 weeks. The responders to treatment served as group 1 and nonresponders received solifenacin 10 mg for an additional 6 weeks. Responders and nonresponders to the 10-mg treatment were defined as groups 2 and 3 respectively. NGF was measured after each treatment using the ELISA method and normalized by the urinary creatinine levels (NGF/Cr).

Results

There were 21, 22 and 16 patients in groups 1, 2, and 3 respectively. At baseline, the NGF and NGF/Cr levels were higher in groups 1, 2, and 3 compared with the controls. After the solifenacin 5 mg treatment, the NGF and NGF/Cr levels of group 1 individuals decreased to those of the control level. After increasing the dosage of solifenacin to 10 mg in group 2, the NGF and NGF/Cr levels decreased to normal levels. In group 3 (patients who did not responded to any treatment), these levels remained unchanged.

Conclusions

Our results suggest that urinary NGF could be a potential biomarker for monitoring the treatment of symptoms in OAB patients who are treated with solifenacin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

AM:

Antimuscarinic

BoNT-A:

Botulinum toxin-A

Cr:

Creatinine

DOA:

Detrusor overactivity

IQR:

Interquartile range

NGF:

Nerve growth factor

OAB:

Overactive bladder

OAB-V8:

Overactive Bladder Awareness Tool

References

  1. Chapple CR, Artibani W, Cardozo LD, Castro-Diaz D, Craggs M, Haab F, Khullar V, Versi E (2005) The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 95(3):335–340. doi:10.1111/j.1464-410X.2005.05294.x

    Article  PubMed  Google Scholar 

  2. De Wachter S, Wyndaele JJ (2003) Frequency-volume charts: a tool to evaluate bladder sensation. Neurourol Urodyn 22(7):638–642. doi:10.1002/nau.10160

    Article  PubMed  Google Scholar 

  3. Nixon A, Colman S, Sabounjian L, Sandage B, Schwiderski UE, Staskin DR, Zinner N (2005) A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 174(2):604–607. doi:10.1097/01.ju.0000165461.38088.7b

    Article  PubMed  Google Scholar 

  4. Hashim H, Abrams P (2006) Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 175(1):191–194. doi:10.1016/S0022-5347(05)00067-4, discussion 194–195

    Article  CAS  PubMed  Google Scholar 

  5. Steers WD, Kolbeck S, Creedon D, Tuttle JB (1991) Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J Clin Invest 88(5):1709–1715. doi:10.1172/JCI115488

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Kim JC, Park EY, Seo SI, Park YH, Hwang TK (2006) Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 175(5):1773–1776. doi:10.1016/S0022-5347(05)00992-4, discussion 1776

    Article  CAS  PubMed  Google Scholar 

  7. Liu HT, Chancellor MB, Kuo HC (2009) Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int 103(12):1668–1672. doi:10.1111/j.1464-410X.2009.08380.x

    Article  CAS  PubMed  Google Scholar 

  8. Liu HT, Chancellor MB, Kuo HC (2009) Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol 56(4):700–706. doi:10.1016/j.eururo.2008.04.037

    Article  CAS  PubMed  Google Scholar 

  9. Coyne KS, Zyczynski T, Margolis MK, Elinoff V, Roberts RG (2005) Validation of an overactive bladder awareness tool for use in primary care settings. Adv Ther 22(4):381–394

    Article  PubMed  Google Scholar 

  10. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50(6):1306–1314. doi:10.1016/j.eururo.2006.09.019, discussion 1314–1305

    Article  PubMed  Google Scholar 

  11. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20(6):327–336. doi:10.1007/s00345-002-0301-4

    CAS  PubMed  Google Scholar 

  12. Yokoyama T, Kumon H, Nagai A (2008) Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder. Neurourol Urodyn 27(5):417–420. doi:10.1002/nau.20519

    Article  PubMed  Google Scholar 

  13. Liu HT, Kuo HC (2008) Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol 179(6):2270–2274. doi:10.1016/j.juro.2008.01.146

    Article  PubMed  Google Scholar 

  14. Oktar T, Kocak T, Oner-Iyidogan Y, Erdem S, Seyithanoglu M, Ziylan O, Kocak H (2013) Urinary nerve growth factor in children with overactive bladder: a promising, noninvasive and objective biomarker. J Pediatr Urol 9(5):617–621. doi:10.1016/j.jpurol.2012.06.003

    Article  PubMed  Google Scholar 

  15. Vijaya G, Cartwright R, Derpapas A, Gallo P, Fernando R, Khullar V (2013) Changes in nerve growth factor level and symptom severity following antibiotic treatment for refractory overactive bladder. Int Urogynecol J 24(9):1523–1528. doi:10.1007/s00192-012-2038-y

    Article  CAS  PubMed  Google Scholar 

  16. Walsh CA, Siddins A, Parkin K, Mukerjee C, Moore KH (2011) Prevalence of "low-count" bacteriuria in female urinary incontinence versus continent female controls: a cross-sectional study. Int Urogynecol J 22(10):1267–1272. doi:10.1007/s00192-011-1506-0

    Article  PubMed  Google Scholar 

  17. Hessdoerfer E, Jundt K, Peschers U (2011) Is a dipstick test sufficient to exclude urinary tract infection in women with overactive bladder? Int Urogynecol J 22(2):229–232. doi:10.1007/s00192-010-1263-5

    Article  PubMed  Google Scholar 

  18. Liu HT, Lin H, Kuo HC (2011) Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy. Neurourol Urodyn 30(8):1525–1529. doi:10.1002/nau.21118

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Ethical statement

This study was approved by the Clinical Research Ethics Committee of the University of Kocaeli.

Author information

Authors and Affiliations

  1. Department of Urology, Sivas Numune Hospital, Sivas, Turkey

    Seyfettin Ciftci

  2. Department of Urology, School Medicine, University of Kocaeli, Kocaeli, Turkey

    Cuneyd Ozkurkcugil, Hasan Yilmaz, Murat Ustuner, Ufuk Yavuz & Mustafa Yuksekkaya

  3. Department of Biochemistry, School of Medicine, University of Kocaeli, Kocaeli, Turkey

    Mustafa Baki Cekmen

Authors
  1. Seyfettin Ciftci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cuneyd Ozkurkcugil
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hasan Yilmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Murat Ustuner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ufuk Yavuz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mustafa Yuksekkaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mustafa Baki Cekmen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seyfettin Ciftci.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ciftci, S., Ozkurkcugil, C., Yilmaz, H. et al. Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder. Int Urogynecol J 27, 275–280 (2016). https://doi.org/10.1007/s00192-015-2825-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-015-2825-3

Keywords

Search

Navigation